Identification of Subjects with Insulin Resistance and β-Cell Dysfunction Using Alternative Definitions of the Metabolic Syndrome

Diabetes

Volumn 52, Issue 11, 2003, Pages 2740-2747

  Hanley, Anthony J G ^a,b   Wagenknecht, Lynne E ^c   D'Agostino Jr , Ralph B ^c   Zinman, Bernard ^b   Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; ETHNOLOGY; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BLOOD PRESSURE; BODY CONSTITUTION; BODY MASS INDEX; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; FEMALE; HISPANIC AMERICANS; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 0242363615     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.11.2740     Document Type: Article

References (52)

1. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898, 1990
2. Stern MP: Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44:369-374, 1995
3. World Health Organization. Definition, Diagnosis and Classification of Diabetes: Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
5. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 152:908-911, 2000
6. Liese AD, Mayer-Davis EJ, Haffner SM: Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 20: 157-172, 1998
7. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
8. Ford ES, Giles WH: A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26:575-581, 2003
9. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427-436, 2003
10. Karter AJ, Mayer-Davis EJ, Selby JV, D'Agostino RB Jr, Haffner SM, Sholinsky P, Bergman R, Saad MF, Hamman RF: Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women: the Insulin Resistance and Atherosclerosis Study. Diabetes 45:1547-1555, 1996
11. Howard BV, Mayer-Davis EJ, Goff D, Zaccaro DJ, Laws A, Robbins DC, Saad MF, Selby J, Hamman RF, Krauss RM, Haffner SM: Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Metabolism 47:1174-1179, 1998
12. Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV: Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 14:1940-1945, 1994
13. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594-1600, 1997
14. Hanley AJ, Karter AJ, Festa A, D'Agostino R Jr, Wagenknecht LE, Savage P, Tracy RP, Saad MF, Haffner S: Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes 51:2642-2647, 2002
15. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
16. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156:1070-1077, 2002
17. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B: The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 20:2140-2147, 2000
18. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
19. Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51:3120-3127, 2002
20. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V: Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 165:285-292, 2002
21. Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM, Henkin L, Howard G, Savage PJ, Saad MF, Bergman RN, Hamman R: The Insulin Resistance Atherosclerosis Study: design, objectives and recruitment results. Ann Epidemiol 5:464-472, 1995
22. Haffner SM, D'Agostino R Jr, Saad MF, Rewers M, Mykkanen L, Selby J, Howard G, Savage PJ, Hamman RF, Wagenknecht LE, Bergman RE: Increased insulin resistance and insulin secretion in nondiabetic African Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes 45:742-748, 1996
23. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998
24. Bergman RN, Finegood DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-86, 1985
25. Welch S, Gebhart SSP, Bergman RN, Phillips LS: Minimal model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508-1518, 1990
26. Steil GM, Volund A, Kahn SE, Bergman RN: Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes 42:250-256, 1993
27. Pacini G, Bergman RN: MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsitivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23:113-122, 1986
28. Zaccaro DJ, D'Agostino RB Jr, Karter A, Bergman R, Wagenknecht LE: A comparison of the repeatability of insulin sensitivity with other cardiovascular disease risk factors (Abstract). Can J Cardiol 13 (Suppl. B):197B, 1997
29. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YD, Sands RE, Pei D, Savage PJ, Bergman RN: A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 43:1114-1121, 1994
30. Korytkowski MT, Berga SL, Horwitz MJ: Comparison of the minimal model and the hyperglycemic clamp for measuring insulin sensitivity and acute insulin response to glucose. Metabolism 44:1121-1125, 1995
31. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456-1467, 1981
32. Kahn SE, Prigeon RL, McCulloch DK: Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
33. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres J-P: A single threshold value of waist girth identifies normal weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 64:685-693, 1996
34. Herbert V, Lau K, Gottlieb C, Bleicher S: Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375-1384, 1965
35. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int 58: 1703-1710, 2000
36. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959-965, 1993
37. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 44:837-845, 1988
38. Shafrir E: Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Diabetes Metab 22:122-131, 1996
39. Zimmet P, Boyko EJ, Collier GR, de Courten M: Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 892:25-44, 1999
40. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM: Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 97:996-1001, 1998
41. Hanley AJ, Williams K, Stern MP, Haffner SM: Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25:1177-1184, 2002
42. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988-1992, 1993
43. Banerji MA, Lebovitz HE: Insulin action in black Americans with NIDDM. Diabetes Care 15:1295-1302, 1992
44. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, Rewers M, Mykkanen L, Karter AJ, Hamman R, Saad MF: Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes 46:63-69, 1997
45. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
46. Hanley AJ, D'Agostino R Jr, Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM: Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the Insulin Resistance Atherosclerosis Study. Diabetes 51:1263-1270, 2002
47. Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV: Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations: Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arterioscler Thromb Vasc Biol 17:64-71, 1997
48. Unger RH: Lipotoxic diseases. Annu Rev Med 53:319-336, 2002
49. Mayer-Davis EJ, Levin S, Bergman RN, D'Agostino RB Jr, Karter AJ, Saad MF: Insulin Resistance Atherosclerosis Study (IRAS): insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab Res Rev 17:137-145, 2001
50. Diabetes Prevention Program Investigators: The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634, 1999
51. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
52. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001